Empowering Innovators
Welcome to Springboard Health Ventures. In healthcare investing, experience, networks, and expertise matter. We have unparalleled access to these ingredients thanks to our tight group of Angels.
Our fund leverages and amplifies the work of the Springboard Health Angels, a syndicate we have been operating since 2022, and that has invested in dozens of healthcare startup across Europe and the US.
Our Journey Begins Here
Springboard Health Ventures is a pioneering fund established with the goal of transforming startup ideas into successful businesses. We collaborate closely with Springboard Health Angels to identify, nurture, and invest in promising companies, aiming to revolutionize the healthcare and technology sectors.
Dr. Yoni Goldwasser
General Partner
Dr. Andreas Schimdt
General Partner
Our thesis
Biopharma value chain
Biopharma represents a substantial and rapidly growing component of global healthcare spending, currently accounting for 10-20% of total healthcare expenditures and projected to reach approximately $2.3 trillion by 2028. Despite these significant investments, the biopharma value chain remains plagued by inefficiencies and suboptimal effectiveness across research, development, manufacturing, and commercialization stages. Integrating advanced technologies, particularly Generative AI, presents a substantial opportunity to drive efficiency and effectiveness, potentially unlocking over $100 billion in value for the biopharma industry. By investing in startups that leverage these technologies to streamline processes, enhance productivity, and improve patient outcomes, we aim to tap into this transformative potential
Smarter healthcare systems
Healthcare services constitute a massive global market valued at up to $7 trillion, yet a significant portion of this expenditure is lost to inefficiencies and fails to effectively reach those most in need. A critical factor in these inefficiencies is the growing challenge in delivering care, exacerbated by widespread staff shortages and increasing burnout among healthcare workers. This presents a compelling opportunity for technological solutions, particularly artificial intelligence. Industry leaders clearly recognize the transformative potential of these innovations: for instance, an overwhelming 88% of healthcare organizations anticipate positive returns on investment from implementing generative AI technologies, underscoring the strategic importance and viability of investing in tech-driven healthcare solutions.
Deep tech paradigm changers
Emerging technologies in robotics, mixed reality, and other frontier areas periodically open unique windows to develop groundbreaking healthcare products and services. Investing in multidisciplinary teams of exceptional talent who can bridge the gap between academic innovation and clinical application is essential. Such teams have the potential not only to transform clinical workflows and significantly enhance patient care but also to fundamentally improve outcomes, making these opportunities strategically critical for our fund’s focus and for healthcare advancement as a whole.
Biodefense and dual-use tech
The biodefense and dual-use biotechnology market is set to more than double, surpassing $50 billion by 2035, driven by a robust compound annual growth rate of 7–10%. Key drivers of this growth include increased government investment following the COVID-19 pandemic, broader adoption in civilian markets, and heightened awareness of biological threats. Recognizing the substantial potential in this rapidly expanding space, Springboard Health Ventures strategically targets dual-use innovations, focusing particularly on areas such as vaccines, synthetic biology platforms, AI-powered diagnostics, and biosecurity software, which collectively offer high-impact opportunities for both commercial success and enhanced global health security.